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ABSTRACT OF THE THESIS 
 
The Association of Gut Microbiome Composition  
and Parkinson’s Disease in Patient Cohort  
of Central California 
 
By 
 
Hsiang-Chin Chou 
 
Master of Science in Epidemiology 
University of California, Los Angeles, 2019 
Professor Beate Ritz, Chair 
 
The gut microbiome recently has been associated with many diseases, with studies showing that 
the microbiome can affect aspects of neurological function, brain activity, and behavior. While 
several digestive symptoms are well-known non-motor features of Parkinson’s disease (PD), the 
role of the gut microbiome in the neurodegenerative process of PD remains underexplored. Here 
we recruited a cohort of 81 PD patients and 56 healthy controls from central California. We 
collected ethanol fixed fecal samples and conducted microbial composition analyses. Beta 
diversity analysis demonstrated compositional differences in the microbiome of PD patients and 
controls. We also identified specific bacterial genera that were associated with PD status using 
negative binomial models to determine the differential abundance of taxa (DESeq2 package in R; 
 iii 
B-H adjusted p-value < 0.05). We also identified specific bacterial genera significantly different 
in abundance between higher levodopa equivalent dose (LED) use PD patients and lower LED use 
PD patients. Furthermore, several specific bacterial families were found to be highly correlated 
with a constipation score in PD patients and controls. In conclusion, we found differences in the 
gut microbiome composition comparing PD cases and controls and identified specific bacterial 
genera that seemed to be associated with PD status. In the future, investigations are needed to 
identify underlying pathophysiologic pathways influenced by the gut microbiome in PD. 
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1. Introduction 
Parkinson’s Disease (PD) is a neurodegenerative disorder with progressive motor 
impairment and non-motor symptoms, including cognitive decline, mood disorders1, and gastro-
intestinal (GI) features such as constipation and gastro-paresis. The pathologic hallmarks of 
neurodegeneration in PD, namely Lewy bodies and α-synuclein aggregates, have also been found 
in the gut of PD patients2-4. While constipation, gastroparesis, and other digestive symptoms are 
well-known non-motor features of PD, the role the gut microbiome may play in the 
neurodegenerative process remains underexplored, even though several studies have pointed out 
the importance of the gut microbiome in PD5-15. In those previous studies, few of the patients lived 
in the United States13,14 and microbiota may have differed due to many regional/cultural influences. 
Furthermore, studies differed in their protocols and analysis approaches and study results were not 
entirely consistent8-15. Although the gut microbiome is relatively stable in general, it has been 
shown to be influenced by various factors such as genetic make-up of the host, diet, medication 
use and the environment in general16-18.  
We conducted a study to investigate the gut microbiome in PD in a largely rural California 
population with the goal to determine differences in microbiome composition between PD patients 
and age-matched household and population controls who participated in a case-control study in 
central California as part of the population‐based Parkinson's Environment and Gene study19,20.  
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2. Method 
2.1 Participant recruitment and data collection 
All procedures described were approved by the University of California at Los Angeles 
(UCLA) Institutional Review Boards (IRBs). Informed consent was obtained from all participants. 
PEG is a community-based study located in central California counties (Kern, Fresno, and 
Tulare)19,20. 
Idiopathic Parkinson’s disease patients were first recruited early in disease (within the first 
5 years after diagnosis) into the Parkinson’s Environment and Genes study between 2001 and 2015 
and then followed for disease progression (on average for 5-7 years after initial enrollment); those 
seen in 2017-2018 were also asked to provide a fecal sample.  From 2001-2007, newly diagnosed 
PD cases were recruited through local neurology medical group, medical centers and the Veterans 
Affairs hospital. Between 2011-2017, we recruited newly diagnosed PD patients with the help of 
the California PD registry (CAPDR). Patient eligibility criteria were: (1) PD diagnosis in the past 
3-5 years; (2) resident of one of three central California counties (Kern, Fresno, and Tulare); (3) 
examined and diagnosed by a UCLA PEG study movement disorder specialists; (4) no serious 
psychiatric conditions (including dementia before motor onset); (5) not terminally ill or 
institutionalized. We enrolled participants for this gut microbiome study in 2017-2018 and 
collected fecal samples if they met the following additional criteria: (1) no serious inflammatory 
bowel disease history (e.g. Crohn’s Disease or ulcerative colitis); (2) no antibiotics use history or 
infections in the past three months before stool sample collection; (3) not currently under 
immunosuppressant medication21.  
We also recruited unaffected household controls (N = 39) for as many PD cases as possible. 
These controls were relatively well matched by age but gender disparate (spouses N = 38) and one 
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daughter. Inclusion criteria for household controls were: (1) no neurodegenerative disease; (2) 
currently living in the same household as the PD patient; and (3) met the same criteria for fecal 
sample collection described above for cases. Population-based controls (N = 17) were originally 
recruited between 2009-2011 from the same three counties, mostly selected randomly from the 
county’s residential tax records and re-contacted for this study in 2017-18. These controls were 
required to meet the same eligibility criteria as household controls except for living in a patients’ 
household.  
In total, we enrolled 137 participants, including 81 Parkinson’s disease patients and 56 
unaffected controls (39 household and 17 population-based controls). 
At the time of sample collection, we also collected additional data including the Geriatric 
Depression Scale-15 (GDS-15), the Wexner constipation questionnaire (Cleveland Clinic 
constipation scoring system)22, and recorded antibiotic usage history and behavioral (e.g. smoking, 
caffeine, physical activity), medical (comorbidities), and environmental factors from all 
participants.  
2.2 Dietary assessment 
 We administered to all subjects a validated paper-based Diet History Questionnaire 
II (DHQ II, https://epi.grants.cancer.gov/dhq2/); a food frequency questionnaire (FFQ) developed 
by the Risk Factor Assessment Branch (RFAB) in the National Cancer Institute (NCI). The DHQ 
II consists of 134 food items and 8 dietary supplement questions that asks to report the intake of 
food items (and portion sizes) in the past month. These data can be analyzed with a Diet*Calc 
Software (version 1.5.0) developed by NCI that generates nutrient and food group intake estimates 
for the DHQ II.  
2.3 Fecal sample collection  
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All samples analyzed here were collected between November 2017 and November 2018. 
Participants were provided with a fecal collection kit to be used at their home at their convenience. 
Specifically, they are asked to urinate first, then defecate into a Fisher-brand Commode Specimen 
Collection System, or the Fe-Col® Faeces Collection Paper and transfer the feces to a Para-Pak 
stool collection cup prefilled with 20 ml of 95% ethanol solution to stabilize the sample, allowing 
for storage at room temperature for up to two weeks23. The stabilized samples were mailed and 
delivered to UCLA at room temperature in padded envelopes and stored in a -80°C freezer right 
after having been received. 
2.4 Bacterial 16S rRNA sequencing and processing 
From the ethanol-preserved feces samples, 0.25g underwent DNA extraction by bead 
beating with the MO BIO Powersoil kit. The V4 hypervariable region of the 16S rRNA gene was 
amplified using the 515F and 806R primers (5’-GTGCCAGCMGCCGCGGTAA-3’ and 5’-
GGACTACHVGGGTWTCTAAT-3’, respectively) according to a published protocol24. PCR 
products were purified by a commercial kit and sequenced on the Illumina HiSeq 2500 platform. 
In most microbial species, the V4 region is approximately 253 bp, and only deviates from this 
length by a few base pairs. Because the HiSeq 2500 rapid run mode enables paired 150-bp reads, 
the reads overlap to generate high-quality, full-length sequences of the entire region. The 806R 
primer includes a unique sequence tag to barcode the samples, enabling 200-400 specimen to be 
run as one batch with a targeted depth of 250,000 sequences/sample.  
Sequence data with quality information (i.e. FASTQ) are imported into QIIME 2.0 for 
sequence quality filtering in Casava 1.8 demultiplexed (paired-end) format. In the pipeline of 
DADA2, in an effort to remove noise in paired-end sequences and for quality control, no bases 
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from the beginning of the sequences were trimmed; sequences were truncated from 245 bases 
forward and 55 bases backward due to the expected decrease in quality. 
The taxonomic assignments of sequences are performed using open reference operational 
taxonomic unit (OTU) picking in QIIME 2.0 against the SILVA 132 99% database 
(https://www.arb-silva.de/). The range of our demultiplexed sequence counts from the Illumina 
HiSeq 2500 platform was between 102,017 and 433,935 (median = 185,928), and a total of 5421 
OTUs were picked.  
2.5 Statistical analysis methods for microbial community composition and abundance  
Relative abundance of operational taxonomic units (OTUs, which correspond roughly to 
species), genera, and also at higher taxonomic levels were computed for each study participant 
using QIIME 2.0 software. A rooted phylogenetic tree was generated to analyze phylogenetic 
diversity. To test the alpha diversity (the diversity within each individual sample, expressed by the 
richness of species) within the PD case group and within a control group, different metrics were 
used to evaluate each sample’s species richness including the measures known as the Observed 
OTUs, Chao1 index, Shannon index, and Faith’s phylogenetic diversity; we also generated 
visualizations via boxplots. Microbial composition (i.e. between group diversity; beta diversity) 
will be compared across all samples using unweighted and weighted UniFrac (a phylogenetic 
distance metric), Bray-Curtis and Canberra distances and visualizations via non-metric 
multidimensional scaling (NMDS) and principal coordinate (PCoA) plots.  
Microbiota composition difference (beta diversity) in relation to PD status (PD vs Control 
Groups) and covariates was assessed using multivariate permutational analysis of variance 
(PERMANOVA)25, which is a non-parametric method based on dissimilarities, and also allows 
for complex analytical designs adjusting for covariates and for partitioning of variability. The 
 6 
phyloseq package in R26, integrated within the DESeq2 package were employed to test the 
differential abundance of taxa comparing PD with control group samples. Differences were 
determined at the genus level using a negative binomial distribution (Benjamini-Hochberg 
adjusted p-value < 0.05) and we provided log2 fold change plots to display significant microbiota 
differences. To adjust for potential confounders, the microbiota identified from DESeq2 were 
evaluated after adjustment for covariates (sex and race) using the likelihood-ratio test. 
Microbiota composition difference (beta diversity) in relation to disease duration or 
evodopa equivalent dose among PD patients were also assessed using PERMANOVA. 
Differences in microbiota at the genus level between those with a longer (10+ years) or shorter 
disease duration (< 10 years) were also determined with the DESeq2 package in R and displayed 
with log2 fold change plots. 
 We also assessed Spearman’s correlations between microbiota relative abundance and 
clinical characteristics.  
The 36 cases and their household controls were considered matched pairs and we also 
assessed differences in microbiota composition using both pair-wise PERMANOVA and DESeq2 
to identify bacteria possibly related to Parkinson’s disease. 
 
3. Results 
3.1. Demographic characteristics 
 Demographic characteristics of the study cohort are presented in Table 1. The participants 
are mainly of European ancestry (77.4%), which comprises the majority of the elderly population 
of the central California counties (i.e. Kern, Fresno, and Tulare). There were more males among 
PD patients (64.2%) than controls (37.5%), which reflects the higher prevalence of PD in men and 
the fact that household controls were opposite gender spouses. The PD patients (mean age 72.1 
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years) were on average 4 years older than the controls (mean age 68.7 years), but had similar 
education levels (14.4 years vs. 14.9 years in all controls). The PD patients had on average a higher 
constipation score (mean Wexner constipation score = 6.69 vs. 4.38 in all controls) and a lower 
BMI (27.36 vs. 29.6 in all controls). Among PD patients 61.7% and among controls 66.0% had 
never smoked. In terms of the dietary history, PD patients on average reported a higher intake of 
energy (kcal) and carbohydrates (g) than all controls, while the population controls on average 
reported a higher intake of total fat (g), protein (g) and dietary fiber (g). Concerning their clinical 
characteristics, PD patients, on average were first diagnosed at age 62.7 (± 10.9) years, and at the 
time of the fecal sampling their mean disease duration was 9.4 (± 4.1) years, and their average 
Levodopa equivalent dose (LED) was 985.35 mg (median = 690 mg). Most of the PD patients 
(90%) were treated with Levodopa/Carbidopa/Entacapone only or along with dopamine agonist, 
while 5% used Dopamine Agonists only and 5% used none. 
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Table 1. Demographic characteristics in PD patients and healthy controls (N = 137) 
    Total (N=137) PD case (N=81) Household control (N=39) 
Population 
control (N=17) 
Characteristic of Cases N Mean (SD) N 
Mean 
(SD) N 
Mean 
(SD) N  
Mean 
(SD) 
PD Diagnosis Age - - 81 62.7 (10.9) - - - - 
Disease duration - - 81 9.4 (4.1) - - - - 
L-dopa equivalent dose (mg) - - 81 985.4 (866.4) - - - - 
  N % N % N % N % 
PD Type         
 Probable PD - - 27 33.3 - - - - 
 Definite PD - - 54 66.7 - - - - 
Motor Subtype         
 Tremor dominant - - 33 41.3 - - - - 
 PIGD* - - 40 50 - - - - 
 Indeterminate - - 7 8.8 - - - - 
Disease duration         
 Long (10 years+) - - 29 35.8 - - - - 
 Short (less than 10 
years) - - 52 64.2 - - - - 
L-DOPA and DA          
 Only DA - - 4 4.9 - - - - 
 Only L-DOPA or both  - - 73 90.1 - - - - 
 None - - 4 4.9 - - - - 
Characteristic of all 
participants N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N  
Mean 
(SD) 
Age  137 70.8 (9.1) 81 
72.14 
(10.9) 39 
69.1 
(8.9) 17 
68.2 
(6.2) 
Education (Years) 134 14.5 (4.4) 81 
14.35 
(4.7) 36 
14.8 
(4.2) 17 
14.9 
(3.8) 
BMI  129 28.3 (5.9) 77 
27.36 
(5.2) 35 
29.7 
(7.5) 17 
29.4 
(4.4) 
GDS score at fecal collection 129       6.2 (2.1) 78 
6.55 
(2.4) 34 
5.5 
(1.1) 17 
5.7 
(1.5) 
Constipation score 123 5.7 (4.2) 68 
6.69 
(4.1) 38 
4.4 
(4.1) 17 
4.4 
(3.7) 
Energy (kcal) 108 1892.3 (879.9) 61 
1975.8 
(919.8) 32 
1728.9 
(826.3) 15 
1901.3 
(826.3) 
Total fat (g) 108 78.6 (42.4) 61 
79.1 
(43.9) 32 
75.4 
(43.3) 15 
83.1 
(35.9) 
Carbohydrate (g) 108 222.3 (103.3) 61 
245.8 
(110.5) 32 
188.0 
(82.2) 15 
200.3 
(93.0) 
Protein (g) 108 71.5 (37.9) 61 
71.2 
(37.3) 32 
68.0 
(38.3) 15 
79.9 
(40.4) 
Dietary fiber (g) 108 17.5 (9.4) 61 
17.6 
(8.8) 32 
16.9 
(10.9) 15 
17.9 
(8.5) 
  N % N % N % N % 
Sex          
 Male 73 53.3 52 64.2 11 28.2 10 58.8 
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 Female 64 46.7 29 35.8 28 71.8 7 41.2 
Race          
 European/White 103 77.4 65 80.3 27 77.1 11 64.7 
 Hispanic 23 17.3 13 16.1 6 17.1 4 23.5 
 Asian 5 3.8 2 2.5 2 5.7 1 5.9 
 Native American 2 1.5 1 1.2 0 0 1 5.9 
Smoking Status         
 Ever (Quit or current) 49 36.6 31 38.3 11 30.6 7 41.2 
 Never 85 63.4 50 61.7 25 69.4 10 58.8 
Relatives With PD         
 None 100 76.9 53 68.0 33 94.3 14 82.4 
 Primary relative 23 17.7 19 24.4 1 2.9 3 17.7 
  Non-primary relative 7 5.4 6 7.7 1 2.9 0 0 
*PIGD: Postural Instability and Gait Dysfunction 
*DA: Dopamine Agonist  
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3.2. Gut microbiome composition between PD patients and controls 
Overall, there were no statistically significant differences in four different indices of alpha 
diversity (the richness of species) according to the Kruskal-Wallis test for observed OTUs, Chao1 
index, Shannon index, or Faith’s phylogenetic diversity between PD patients and all controls. The 
results are visualized with boxplots in Figure 1.  
To assess the overall microbial species composition differences between PD patients and 
controls across all samples, PERMANOVA tests (repeated with 100,000 permutations) were 
conducted using four different metrics (Bray-Curtis and Canberra distances, unweighted and 
weighted UniFrac distance metrics). Statistically significant differences were found with three 
different metrics (Bray-Curtis: P = 0.03, Canberra: P = 0.001, and Unweighted UniFrac: P = 0.02) 
before adjusting for covariates (Table 2 (A)). Figure 2 visualizes the microbial composition 
differences via non-metric multidimensional scaling (NMDS) plots and principal coordinate 
(PCoA) plots.  
 To adjust for potential confounders, additional PERMANOVA tests were performed  
adjusting for sex, race and age, and again statistically significant microbial species composition 
differences were found between PD patients and controls in two metrics (Bray-Curtis: P = 0.02 
and Canberra: P = 0.001) and marginally significant in the unweighted UniFrac (P = 0.06) (Table 
2 (B)-(C)). Further adjusting for carbohydrate intake and constipation score, the results remained 
statistically significant Bray-Curtis (P = 0.04) and Canberra (P = 0.002), but not in unweighted 
UniFrac (P = 0.099).  
We also investigated the effect of disease duration on the microbial composition difference 
among PD patients (N = 81) only after adjusting for diagnosis age and race with PERMANOVA. 
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However, no differences were found for disease duration in all four metrics (Bray-Curtis: P = 0.98, 
Canberra: P = 0.98, Unweighted UniFrac: P = 0.93, Weighted UniFrac: P = 0.93; Table 2 (D)).  
In addition, we analyzed the microbiome composition among those patients who were 
currently taking PD medications using PERMANOVA. We quantified each patient’s dosage of 
PD medications by calculating the levodopa equivalent doses (LED)27. We found statistically 
significant associations between microbial species composition and LED with three metrics (Bray-
Curtis: P = 0.02, Canberra: P = 0.003, Unweighted UniFrac: P = 0.001; Table 2 (E)). 
3.3. Identification of differentially abundant taxa at family or genus level between PD versus 
controls 
Analyses of the differential abundance of taxa at the genus level comparing PD with all 
control samples and using the negative binomial distribution (B-H adjusted p-value < 0.05) 
revealed that several bacteria differed statistically significantly between the 2 groups, after 
adjusting for sex and race. The bacterial taxa with a statistically significant abundance increase 
among PD cases included 10 genera (Akkermansia, Alistipes, Parabacteroides, Enterococcus, 
Family XIII AD3011 group, Hungatella, UBA1819, 3 unclassified at genus level), which belonged 
to 9 families (Akkermansiaceae, Eggerthellaceae, Enterococcaceae, Family XIII, 
Lachnospiraceae, Muribaculaceae, Tannerellaceae, Rikenellaceae, Ruminococcaceae) and 4 
phyla (Actinobacteria, Bacteroidetes, Firmicutes, Verrucomicrobia). Those with a statistically 
significant decrease in abundance in PD cases included 4 genera (Butyricicoccus, 
Erysipelotrichaceae UCG-003, Fusicatenibacter, Lachnospiraceae NK4A136 group), which 
belonged to 3 families (Erysipelotrichaceae, Lachnospiraceae, Ruminococcaceae) and 1 phylum 
(Firmicutes). Shifts in the identified microbial abundances in PD patients versus controls are 
displayed with log2 fold change plots in Figure 3 (A).  
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We further performed analysis to test the differential abundance of taxa at the genus level 
in PD patients with PD duration time 10 years or longer compared with control group samples. 
The bacteria with significant abundance increase in longer disease duration cases included 4 genera 
(Enterococcus, Lactobacillus, Parabacteroides, 1 unclassified at genus level), which belonged to 
4 families (Enterococcaceae, Lachnospiraceae, Tannerellaceae, Ruminococcaceae) and 2 phyla 
(Bacteroidetes, Firmicutes). The bacteria with significant abundance decrease in longer disease 
duration cases included 3 genera (Lachnospiraceae NK4A136 group, Roseburia, [Eubacterium] 
ruminantium group), which all belonged to the family Lachnospiraceae and the phylum 
Firmicutes. Comparing PD patients with disease duration less than 10 years to control group 
samples, the bacterial taxa with a statistically significant abundance increase included 10 genera 
(Enterococcus, Lactobacillus, Family XIII AD3011 group, Hungatella, [Eubacterium] 
coprostanoligenes group, Erysipelatoclostridium, Turicibacter, Cloacibacillus, 2 unclassified at 
genus level), which belonged to 9 families (Enterococcaceae, Erysipelotrichaceae, Family XIII, 
Lachnospiraceae, Lactobacillaceae, Muribaculaceae, Ruminococcaceae, Synergistaceae, 1 
unclassified at family level) and 3 phyla (Bacteroidetes, Firmicutes, Synergistetes). The bacterial 
taxa with statistically significant abundance decrease in shorter disease duration cases included 5 
genera (Butyricicoccus, CAG-352, Coprococcus 2, Lachnospiraceae NK4A136 group, Prevotella 
9), which belonged to 3 families (Prevotellaceae, Lachnospiraceae, Ruminococcaceae) and 2 
phyla (Bacteroidetes, Firmicutes). There were 3 genera (Enterococcus, Lachnospiraceae 
NK4A136 group, Lactobacillus) with statistically significant increase or decrease in both the 
longer and shorter disease duration groups. The results are displayed in Figure 3 (B) and (C) and 
the taxa differences are presented in Table 3.  
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We also investigated the differential abundance of taxa at the genus level in PD patients 
currently under PD medication with LED higher than the median (690 mg) compared with LED 
lower than or equal to the median (690 mg). We identified 28 genera with significantly different 
abundance between high LED group and low LED group, in which 26 genera exhibited higher 
abundance in high LED group, and 2 genera ([O: Rhodospirillales] unclassified, Pseudomonas) 
had higher abundance in the low LED group. The detail information of bacteria genera is presented 
in Table 4 and Figure 6. 
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Table 2. PERMANOVA test for association of PD cases and controls with the microbiome, adjusted for potential confounders 
PERMANOVA 
(Permutation = 100,000) Case Control Distance / Matrix 
 
N N Bray Curtis Canberra Unweighted UniFrac Weighted UniFrac 
     R-square P-value R-square P-value R-square P-value R-square P-value 
(A) PD (Yes vs No) 81 56 0.01024 0.03147 * 0.00968 0.00104 ** 0.00959 0.01962 * 0.00481 0.8734 
(B) PD and covariates 81 52                 
 PD     (Yes vs No)     0.01091 0.01951 * 0.01 0.00057 *** 0.00923 0.06328 .  0.0096 0.17691 
 Sex    (male vs female)     0.00838 0.23858 0.00848 0.04754 *   0.00921 0.06647 .  0.00889 0.24921 
 Race (European vs non-
European)     0.00923 0.11122 0.00962 0.00223 **  0.01203 0.00127 ** 0.01003 0.14954 
 Age   (continuous)     0.00998 0.05260 . 0.00802 0.15708 0.00871 0.12547 0.02072 
0.00064 
*** 
(C) PD and covariates 61 47                
 PD    (Yes vs No)     0.01269 0.04204 * 0.01196 0.00165 ** 0.01085 0.09917 . 0.00259 0.99705 
 Sex   (male vs female)     0.00869 0.60741 0.00964 0.26257 0.01137 0.05323 . 0.00738 0.65383 
 Age   (continuous)     0.0106 0.21411 0.01001 0.13092 0.01124 0.06283 . 0.00984 0.35926 
 Race (European vs non-
European)     0.01792 0.58045 0.02012 0.06143 . 0.02253 0.02559 * 0.01393 0.71397 
 Carbohydrate 
(continuous)     0.008 0.77181 0.00809 0.99245 0.00944 0.39299 0.02019 
0.02425 
* 
(D) Patient only 
covariates 81 -               
 
 Disease duration 
(continuous)     0.00854 0.98404 0.01127 0.97753 0.01055 0.93011 0.00713 0.93059 
 Age diagnosed    
(continuous)     0.0157 0.08493 . 0.01266 0.35811 0.01211 0.57193 0.02136 
0.03764 
* 
 Race (European vs non-
European)     0.01532 0.10454 0.0145 0.01607 * 0.01535 0.03829 * 0.01425 0.27955 
(E) Patient only 
covariates 79 -               
 
 Levodopa equivalent 
dosage (continuous)     0.01854 0.01665 * 0.01586 0.0026 ** 0.01874 0.00109 ** 0.01555 0.218 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1         
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Table 3. Significantly identified taxa at genus level by negative binomial distribution regression model 
          PD Case vs Control (Adjusted for sex and race)     
Phylum Class Order Family Genus log2Fold -Change 
Adjusted  
p-value 
  
Actinobacteria Coriobacteriia Coriobacteriales Eggerthellaceae  unclassified 2.838 0.02707   
Bacteroidetes Bacteroidia Bacteroidales Tannerellaceae Parabacteroides 0.961 0.02707   
Bacteroidetes Bacteroidia Bacteroidales Muribaculaceae  unclassified 6.539 0.02707   
Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Alistipes 1.047 0.03581   
Firmicutes Clostridia Clostridiales Lachnospiraceae Fusicatenibacter -1.670 0.00002   
Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus* 4.666 0.00307   
Firmicutes Clostridia Clostridiales Ruminococcaceae UBA1819 1.815 0.00321   
Firmicutes Clostridia Clostridiales Ruminococcaceae Butyricicoccus -0.992 0.02707   
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospiraceae NK4A136 group -1.235 0.02707 
  
Firmicutes Clostridia Clostridiales unclassified unclassified 2.407 0.02707   
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Erysipelotrichaceae UCG-003 -2.018 0.03110 
  
Firmicutes Clostridia Clostridiales Family XIII Family XIII AD3011 group 1.351 0.03982 
  
Firmicutes Clostridia Clostridiales Lachnospiraceae Hungatella 2.449 0.04323   
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Akkermansiaceae Akkermansia* 1.762 0.00489   
          PD duration 10+ years  Case vs Control 
PD duration < 10 years  
Case vs Control 
Phylum Class Order Family Genus log2Fold -Change 
Adjusted  
p-value 
log2Fold 
-Change 
Adjusted  
p-value 
Bacteroidetes Bacteroidia Bacteroidales Tannerellaceae Parabacteroides 1.259 0.0140 - - 
Bacteroidetes Bacteroidia Bacteroidales Muribaculaceae  unclassified  - - 2.643 0.00105 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 9* - - -2.967 0.00047 
Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus 3.601 0.0140 3.130 0.00478 
Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus* 0.473 0.0156 0.269 0.00239 
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospiraceae NK4A136 group -1.759 0.0065 -0.395 0.00044 
Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia* -1.409 0.0329 - - 
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Firmicutes Clostridia Clostridiales Lachnospiraceae [Eubacterium] ruminantium group -1.395 1.17E-12 - - 
Firmicutes Clostridia Clostridiales Ruminococcaceae  unclassified 3.049 0.0140 - - 
Firmicutes Clostridia Clostridiales Family XIII Family XIII AD3011 group - - 1.328 0.03493 
Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus 2* - - -1.777 0.02143 
Firmicutes Clostridia Clostridiales Lachnospiraceae Hungatella - - 3.562 0.04809 
Firmicutes Clostridia Clostridiales Ruminococcaceae Butyricicoccus - - -1.008 0.03046 
Firmicutes Clostridia Clostridiales Ruminococcaceae CAG-352 - - -2.848 0.03381 
Firmicutes Clostridia Clostridiales Ruminococcaceae 
[Eubacterium] 
coprostanoligenes 
group 
- - 1.304 0.03046 
Firmicutes Clostridia Clostridiales unclassified unclassified - - 1.970 0.04495 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Erysipelatoclostridium - - 0.420 0.04973 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Turicibacter - - 1.843 0.03815 
Synergistetes Synergistia Synergistales Synergistaceae Cloacibacillus - - 2.369 6.90E-05 
* same direction of association from previous studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
Table 4. Significantly identified taxa at genus level by negative binomial distribution regression model 
     PD Case (LED > median, 690 mg) vs.  PD Case (LED £ median, 690 mg) 
Phylum Class Order Family Genus log2Fold-Change Adjusted p-value 
Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 0.841 0.049 
Actinobacteria Coriobacteriia Coriobacteriales Atopobiaceae Atopobium 3.623 0.023 
Actinobacteria Coriobacteriia Coriobacteriales Eggerthellaceae Eggerthella 2.632 0.004 
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 0.856 0.039 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 2.513 0.049 
Firmicutes Bacilli Lactobacillales Streptococcaceae Lactococcus 4.549 0.017 
Firmicutes Clostridia Clostridiales Family XIII Family XIII AD3011 group 1.404 0.043 
Firmicutes Clostridia Clostridiales Family XIII [Eubacterium] brachy group 3.245 0.009 
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 1.318 0.002 
Firmicutes Clostridia Clostridiales Lachnospiraceae Eisenbergiella 2.025 0.012 
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnoclostridium 1.915 2E-5 
Firmicutes Clostridia Clostridiales Peptostreptococcaceae Romboutsia 1.723 0.006 
Firmicutes Clostridia Clostridiales Ruminococcaceae Flavonifractor 1.611 0.023 
Firmicutes Clostridia Clostridiales Ruminococcaceae Fournierella 4.949 4.5E-4 
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminiclostridium 5 1.134 0.029 
Firmicutes Clostridia Clostridiales Ruminococcaceae UBA1819 2.514 1E-5 
Firmicutes Clostridia Clostridiales Ruminococcaceae unclassified 2.136 1.171E-3 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Turicibacter 2.104 0.038 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae [Clostridium] innocuum group 2.179 0.049 
Firmicutes Negativicutes Selenomonadales Acidaminococcaceae Succiniclasticum 0.723 0.000 
Firmicutes Negativicutes Selenomonadales Veillonellaceae Dialister 2.768 0.016 
Firmicutes Negativicutes Selenomonadales Veillonellaceae Megasphaera 2.970 0.039 
Firmicutes Negativicutes Selenomonadales Veillonellaceae Veillonella 2.640 0.001 
Proteobacteria Alphaproteobacteria Rhodospirillales unclassified unclassified -2.133 6.49E-14 
Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Bilophila 1.610 0.023 
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Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae unclassified 0.589 0.016 
Proteobacteria Gammaproteobacteria Pseudomonadales Pseudomonadaceae Pseudomonas -6.540 0.002 
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Akkermansiaceae Akkermansia 1.785 0.006 
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3.4. Correlation between taxa and clinical status 
We furthermore used Spearman correlations to assess whether disease duration in PD 
patients and the Wexner constipation score were associated with the gut microbiome abundance 
difference. Although PD duration was found to be positively associated with Bacteroidetes (r = 
0.046, P = 0.686) and negatively associated with Firmicutes (r = -0.066, P = 0.559), the correlations 
were weak and far from statistically significant. For the association of taxa and Wexner 
constipation score, we used the level of  family for correlation analysis in order to compare our 
results with a previously published study8. Our results showed that 4 families (Coriobacteriaceae, 
Eggerthellaceae, Tannerellaceae, Pasteurellaceae) were statistically significantly associated with 
the Wexner score in PD patients (P < 0.05); while in controls, 11 families (Bifidobacteriaceae, 
Marinifilaceae, Rikenellaceae, Tannerellaceae, env.OPS 17, [O: Gastranaerophilales] 
unclassified, Clostridiales vadinBB60 group, Defluviitaleaceae, [O: DTU014] unclassified, 
Acidaminococcaceae, Puniceicoccaceae) were significantly associated with the Wexner score. 
Only Tannerellaceae appeared to be significantly associated with constipation in either group. The 
correlation results are presented in Table 5. 
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Table 5. Correlation between taxa (family level) and Wexner constipation score 
  Case (N = 68)  r P-value 
Family   
 Coriobacteriaceae 0.2473 0.0421 
 Eggerthellaceae 0.4008 0.0007 
 Tannerellaceae 0.2476 0.0418 
 Pasteurellaceae -0.2788 0.0213 
Control (N = 55)  r P-value 
Family   
 Bifidobacteriaceae -0.325 0.0155 
 Marinifilaceae 0.3474 0.0093 
 Rikenellaceae 0.4097 0.0019 
 Tannerellaceae 0.4153 0.0016 
 env.OPS 17 -0.2656 0.05 
 [O: Gastranaerophilales] unclassified 0.3792 0.0043 
 Clostridiales vadinBB60 group 0.2741 0.0429 
 Defluviitaleaceae 0.3872 0.0035 
 [O: DTU014] unclassified 0.3077 0.0223 
 Acidaminococcaceae 0.3449 0.0099 
 Puniceicoccaceae 0.3086 0.0219 
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3.5. Paired case and household control comparisons  
When comparing PD patients with their paired household controls, the gut microbiome 
composition showed a greater alpha diversity (OTU counts, Chao 1, ACE, Shannon/Simpson 
Index) in the paired controls (Figure 4). Overall microbial composition (i.e. beta diversity) was 
compared between cases and household controls in unweighted and weighted UniFrac, and with 
Bray-Curtis distances using PERMANOVA, but there were no statistically significant differences 
found after adjusting for sex and race. However, the pair-wise (N = 36) PERMANOVA showed 
significant differences (p-value = 0.001).  
Using negative binomial models to determine the differential abundance of taxa (B-H 
adjusted p-value < 0.05), we found 2 genera with statistically significant abundance increase in 
PD cases ([O: Rhodospirillales], Lactobacilllus) and 3 genera with statistically significant 
abundance decrease in PD cases (Preveotella 9, CAG-352, [Eubacterium] ruminantium group). 
More specifically, 6 genera (Lachnospiraceae NK4B4 group, Catenibacterium, Catenisphaera, 
[Eubacterium] nodatum group, [F: Puniceicoccaceae] unclassified, [Eubacterium] ruminantium 
group) had statistically significant abundance decreases in longer disease durations PD patients (³ 
10 years). In shorter disease durations PD patients (< 10 years), 2 genera with statistically 
significant abundance increase ([O: Rhodospirillales], Lactobacilllus) and 2 genera with 
statistically significant abundance decrease (CAG-352, [Eubacterium] ruminantium group) were 
identified. The shifts in the identified statistically significant microbial abundances in PD patients 
compared with paired household controls are displayed with log2 fold change plots in Figure 5.  
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Figure 1. Analysis of alpha diversity using Observed OTU counts (left), Chao1 (middle) and 
Shannon index (right). Total of 81 PD patients and 56 controls.  Color indicates the disease duration of 
PD patients (Red:  disease duration 10+ years, green: disease duration <10 years, blue: disease duration 
zero known as controls).
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Figure 2. Visualizations of microbial composition differences via non-metric multidimensional 
scaling (NMDS) plot and principal coordinate (PCoA) plots. (Up-left:  Bray-Curtis distance, up-right:    
Weighted UniFrac, down-left: Canberra distance, down-right: Unweighted-UniFrac; Red: PD patients, 
Green: Household controls, Blue: Population controls).
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(A) Case vs control 
 
 
 
 
 
 
 
 
(B) Long disease duration case vs control 
(C) Short disease duration case vs control 
Figure 3. Shifts in microbial abundances (genus) in PD patients vs household controls. (A) Comparison 
of PD patients (N=81) and controls (N=56). (B) Comparison of PD duration 10 years or longer patients 
(N=29) and household controls (N=56). (C) Comparison of PD duration shorter than 10 years patients 
(N=52) and household controls (N=56). Difference were determined at the genus level using a negative 
binomial distribution (B-H adjusted p-value < 0.05). Horizontal axis shows log2-fold difference in 
abundance between two groups. * indicates consistent result from previous studies8,10,12,28,29. 
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Figure 4. Analysis of alpha diversity using Chao1 (left) and Shannon index (right). Total of 36 PD 
patients and 36 paired household controls. Grey lines are the paired case and control. Greater richness/alpha 
diversity shown in Control group vs PD case, which reflects reduction of gut in PD patients. 
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(A) Case vs household control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Long disease duration case vs household control 
 
 
 
 
 
 
 
 
(C) Short disease duration case vs household control 
Figure 5. Shifts in microbial abundances (genus) in PD patients vs household controls. (A) Comparison 
of PD patients (N=36) and controls (N=36). (B) Comparison of PD duration 10 years or longer patients 
(N=10) and household controls (N=36). (C) Comparison of PD duration shorter than 10 years patients 
(N=26) and household controls (N=36). Difference were determined at the genus level using a negative 
binomial distribution (B-H adjusted p-value < 0.05). Horizontal axis shows log2-fold difference in 
abundance between two groups. * indicates consistent result from previous studies8,10,12,28,29.  
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Figure 6. Shifts in microbial abundances (genus) in high LED PD patients vs low LED PD patients. 
Comparison of higher LED (LED > median, 690 mg) and lower LED (LED £ median, 690 mg). Difference 
were determined at the genus level using a negative binomial distribution (B-H adjusted p-value < 0.05). 
Horizontal axis shows log2-fold difference in abundance between two groups. 
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4. Discussion 
In recent years, researchers started to investigate the relationship between the gut 
microbiome and Parkinson’s disease. However, few studies were conducted with populations 
living in the United States and none in a rural environment. Our population-based case-control 
study provides first data describing the gut microbiota composition of PD patients and two types 
of controls who live in three agricultural counties of California. Although no significant 
differences in alpha diversity measures (species richness of a group) were detected, we found 10 
bacterial taxa at the genus level with statistically significant abundance increases in PD patients 
and 4 bacterial taxa with statistically significant abundance decrease in PD patients compared with 
healthy controls (B-H adjusted p-value < 0.05). Also, 3 bacterial taxa remained statistically 
significant among the shorter disease duration PD patients (< 10 years) and the longer disease 
duration PD patients (10 + years). Interestingly, we found although [O: Rhodospirillales] showed 
statistically significant increase in longer disease duration PD patients (10 + years) vs control, it 
showed statistically significant increase in low LED vs high LED.  
In our study, we found a  reduction of Prevotellaceae (family) and lower Prevotella (genus) 
levels in feces of PD patients with shorter disease duration compared with controls, which is 
consistent with several previous reports8,10,12,28. Decreased Prevotellaceae abundance may also 
correspond to observations of an increased gut permeability in PD patients, which might be due to 
decreased mucin synthesis caused by low Prevotella levels, which in turn increase gut 
permeability9. Lactobacillaceae were more abundant in our PD patients, which is concordant with 
the results from a German study29 and several other studies8,10,13. Akkermansia (genus) were also 
increased in PD patients in our study, in concordance with another German study30. This later 
study compared PD patients in early stages who were L-DOPA drug naïve with age-matched 
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controls and reported that Eubacterium (genus) were remarkably lower in PD patients. We 
however found that this bacterium, Eubacterium [ruminantium group] was statistically 
significantly reduced only in our longer disease duration PD patients compared with controls. 
Interestingly, Eubacterium [coprostanoligenes group], a known cholesterol-reducing anaerobe31, 
was found to be increased in our PD patients with shorter disease duration. Further investigations 
regarding cholesterol levels in our PD cases may help understand the differences we see 
concerning these bacteria. 
A Chicago study of 38 PD subjects (12 drug naive/26 treated with PD meds) and 34 healthy 
controls found some evidence that the anti-inflammatory butyrate-producing bacteria Blautia, 
Roseburia, and Coprococcus are statistically significantly less abundant in PD cases than controls; 
low abundance of SCFA butyrate-producing bacteria in PD patients might also contribute to gut 
leakiness14. In our study, we also found that the genera of Roseburia and Coprococcus were 
significantly less abundant in PD cases than controls, but not Blautia. Additionally, a Finnish 
study8 had reported higher abundance of the family Enterobacteriaceae among patients with a 
postural instability and gait difficulty (PIGD) phenotype compared to patients with a tremor 
dominant (TD) phenotype, suggesting not only that the intestinal microbiome is altered in PD 
subjects but may also play a role in the onset and/or severity of motor symptoms in PD subjects. 
In our study, although we did not identify this phenotype specific association, we found 
Enterobacteriaceae to be increased in our case group. 
For correlations between taxa and clinical disease status, the same study from Chicago 
mentioned above observed that PD duration was highly positively associated with the phylum 
Bacteroidetes and negatively associated with the phylum Firmicutes14. We found that these two 
phyla were associated with PD duration in our cohort in the same direction; however, our results 
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were not statistically significant. We found that compared with controls, PD patients had higher 
constipation scores. Based on the Wexner score for constipation, we found that the families of 
Coriobacteriaceae, Eggerthellaceae, and Tannerellaceae were associated with a higher score, and 
Pasteurellaceae were associated with a lower score rather than the previously reported family 
Ruminococcaceae associated with a higher score in the Finnish study8. Interestingly, among 
controls, 11 different family level taxa were associated with higher Wexner scores. These results 
suggest that intestinal symptoms such as constipation are associated with different microbiota 
composition in PD patients compared with controls. Further investigation may be needed to assess 
whether this is disease specific or not.  
We also investigated gut microbiome composition differences according to patients’ 
current PD medication dose represented by LED. We found that LED was significantly associated 
with microbiome composition represented by beta-diversity analyses for three metrics (Bray-
Curtis: P = 0.02, Canberra: P = 0.003, Unweighted UniFrac: P = 0.001; Table 2 (E)). When 
comparing patients treat at high LED (> median, 690 mg) or low LED (£ median, 690 mg), 28 
bacterial genera showed statistically significant differences in abundance. To our knowledge, this 
is one of the first reports in the field that investigated gut microbiome composition and PD 
medication doses represented by LED. Further exploration is needed to verify these bacterial 
targets and analyze the potential relationship between these bacteria and PD medications. 
Other factors including dietary habits, major infections, immune diseases, host genetics, 
and antibiotics use history may also alter the stability and the composition of the gut 
microbiota16,17,32,33. Diet is thought to be one of the most dominating factors for microbiome 
composition as a study showed that diet changes explained 57% of the total structural variation in 
the gut microbiota34, suggesting profound influences of diet on gut microbiota. In one of the largest 
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studies of gut microbiota in PD, 327 participants (212 PD cases, 136 controls including 54 spouses) 
from the Neuro Genetics Research Consortium study, fruit and vegetable intake were reported to 
have influenced the participants’ microbiome13. In our study, however, we found no between group 
differences in macronutrients (total fat, protein, and carbohydrate), dietary fiber, and calorie intake 
that influenced microbiome composition. We acknowledge the potential limitation of our cohort 
size and the limitations of self-reported dietary information.  
In our study, 36 PD patients were paired with controls living in the same household and 
we were able to conduct pair-wise microbiota composition analyses and compare these with all 
other controls. Interestingly, even though no statistically significant alpha diversity was detected, 
pair-wise comparison of gut microbiome composition for the household control group showed a 
greater richness of control microbiota compared with PD patients. Previous reports have 
demonstrated that there is an undergoing latent inflammatory process in the intestine of PD patients, 
which was considered a trigger factor for α-synuclein misfolding in gut neurons8,14. Our 
observation of a reduction in gut microbiota diversity in PD patients compared with their 
household controls might also be related to disease specific inflammatory processes12,35. In pair-
wise PERMANOVA tests, we identified differences in microbial composition, and we found 
statistically significant between-case-control group differences. Compared with household 
controls only, we also identified 2 genera ([O: Rhodospirillales] unclassified and Lactobacillus) 
with statistically significant abundance increase and 3 genera (Prevotella 9, CAG-352, and 
[Eubacterium] ruminantium group) with abundance decrease in PD patients. Specifically, 
Prevotella showed concordant association in our study (81 cases vs. 56 controls) and previous 
studies8-10,12,28.  
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There are limitations of our current study and findings because there may be other potential 
confounders such as other medication or lifestyle and environmental impacts that we did not adjust 
for in our statistical model. Although we see some differences in gut microbiome composition 
between PD cases and controls, with our relatively moderate sample size (N = 137), our results 
may be more representative of our cohort than the general PD population due to the uniqueness of 
the gut microbiota composition in each individual. Moreover, the differences in methodologic 
approaches (e.g. sequencing platform, QC criteria, analysis methods, etc.) and geographical 
background of the investigated subjects make it difficult to compare our results with the previous 
studies. 
In summary, our study confirms that PD patients have differences in abundance of certain 
gut microbiota compared with controls. Our results largely overlapped with previously reported 
findings in terms of several taxa having shifted in abundance in PD patients relative to controls. 
The household control pair-wise results suggested differences in the gut microbiome of PD patients 
controlling for similar living environments. While current studies provided evidence that 
environmental factors influence neurodegeneration, our future goals are to elucidate whether an 
altered gut microbiome and its function contributes to the onset and/or progression of 
neurodegeneration in PD, and whether the microbiome is affected by chronic environmental 
factors and exposures, specifically the exposure of pesticides since the agricultural central 
California counties are highly exposed. Research to uncover potentially novel etiologies in the 
aspect of gut microbiome for PD may ultimately advance the long-term goal of developing new 
treatment options for PD and neurodegeneration.  
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